---
title: "The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290982899.md"
description: "The stock of Acadia experienced a surge on Friday following an unexpected announcement by European regulators recommending approval of the Rett syndrome drug, Daybu. This surprising development brought Acadia Pharma closer to a breakout, showcasing a positive turn of events for the company."
datetime: "2026-06-26T14:33:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290982899.md)
  - [en](https://longbridge.com/en/news/290982899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290982899.md)
generator: "portal-rs"
---

# The Surprising Reversal That Drove Acadia Pharma Closer To A Breakout

The stock of Acadia experienced a surge on Friday following an unexpected announcement by European regulators recommending approval of the Rett syndrome drug, Daybu. This surprising development brought Acadia Pharma closer to a breakout, showcasing a positive turn of events for the company.

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)

## Related News & Research

- [760,629 Shares in ACADIA Pharmaceuticals Inc. $ACAD Acquired by Bank of New York Mellon Corp](https://longbridge.com/en/news/297610061.md)
- [ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data](https://longbridge.com/en/news/295699458.md)
- [Promise Launches Clinician-Guided BPC-157 Evaluation as FDA Panel Backs 503A Bulks List Addition](https://longbridge.com/en/news/298349678.md)
- [Novartis announces trial setback on del-desiran drug](https://longbridge.com/en/news/298270154.md)
- [Pharvaris rises on late-stage trial win for hereditary angioedema drug](https://longbridge.com/en/news/298315480.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**